Their research was not cited in the patent application. Yet, if this patent application was granted… it could block others… The application, published on May 20 2020, was originally filed on November 15, 2019. (Patent applications are kept secret for 18 months)… the application has claims on organisms genetically modified to produce psilocybin by giving them…
Given promising clinical-trial results, many stakeholders are attempting to patent psychedelic compounds and methods of producing and administering them… the sudden interest in patenting psychedelics has prompted criticism from stakeholders, including patient advocates, scientists, journalists, lawyers and Indigenous communities… Weak psychedelic patents could potentially be invalidated in court, but that does not make them harmless,…
As psilocybin was isolated from the Psilocybe mexicana mushroom in 1957 and is a known compound, it lacks novelty… for being patentable, an invention must be “new” and “inventive”. Since most common psychedelics are known for many years, it is not possible to patent these existing substances (i.e. lack of novelty). The interest in psychedelics…
“The rule is if something already belongs to the public, you can’t take it away from them,” Gretchen Temeles, special counsel at the Philadelphia law firm… said in an interview. But Compass has also highlighted the threat from nonprofits like the Usona Institute, which does its own research on psychedelics. The IPO filing warned that…
As increasing numbers of U.S. states have legalized both medical and adult-use cannabis, another set of Schedule 1 controlled substances – psychedelics – has begun to emerge from the shadows. As was the case for cannabis, biomedical research into psychedelics ground nearly to a halt following the Schedule 1 designation. More than 50 years later and…
…nearly every day, another psychedelics company announces its work in securing patents for the intellectual property represented by the product they developed… a quick search of the USPTO site shows that there are currently hundreds of patents related to LSD and Psilocybin products and formulations. Psilocybin (U.S. Patent No. 3,183,172, “Obtaining Psilocybin and Psilocin from…
The story of CB, a 49-year-old woman, and her roommate, who witnessed the event. CB had contracted Lyme disease in her early 20s, and by the LSD event, she experienced significant pain in her feet and ankles, routinely taking morphine for a decade… CB snorted… pure LSD – 550 times the normal recreational dosage of…
A cannabis researcher who is waging a legal battle to reschedule marijuana in the federal circuit courts said that Bank of America decided to activate her institute’s bank account without explanation or recourse. Dr. Suzanne Sisley, the president and principal investigator at Scottsdale Research Institute [SRI], which is federally licensed to handle and grow cannabis,…
The story of CB, a 49-year-old woman, and her roommate, who witnessed the event. CB had contracted Lyme disease in her early 20s, and by the LSD event, she experienced significant pain in her feet and ankles, routinely taking morphine for a decade… CB snorted… pure LSD – 550 times the normal recreational dosage of…
…the last 3 months, MindMed is down a 31%, ATAI Life Sciences, has plummeted 32%, and Compass Pathways, has fallen 19%. The carnage is not limited to the big 3 players either… It will take 3-5 years for these companies to prove beyond a reasonable doubt that their medicines are both safe and more effective…
Recent Comments